Change in novel filtration markers and risk of ESRD

American Journal of Kidney Diseases

Volumn 66, Issue 1, 2015, Pages 47-54

  Rebholz, Casey M ^a   Grams, Morgan E ^a,b   Matsushita, Kunihiro ^a   Selvin, Elizabeth ^a,b   Coresh, Josef ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

chronic kidney disease (CKD); creatinine; cystatin C; disease progression; end stage renal disease (ESRD); filtration marker; kidney disease outcome; surrogate endpoint; 2 Microglobulin (B2M)

Indexed keywords

BIOLOGICAL MARKER; CREATININE; CYSTATIN C; VASCULOTROPIN; BETA 2 MICROGLOBULIN;

ADULT; ARTICLE; BODY MASS; DISEASE ASSOCIATION; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; RENAL REPLACEMENT THERAPY; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; URINALYSIS; BLOOD; COMORBIDITY; COMPLICATION; DISEASE COURSE; GLOMERULUS; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; PATHOPHYSIOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; QUESTIONNAIRE; RENAL INSUFFICIENCY, CHRONIC; SMOKING; UNITED STATES;

BETA 2-MICROGLOBULIN; BIOMARKERS; COMORBIDITY; CREATININE; CYSTATIN C; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY GLOMERULUS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SMOKING; SURVEYS AND QUESTIONNAIRES; UNITED STATES;

EID: 84937428111     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.11.009     Document Type: Article

References (33)

1. E.J. Lewis, L.G. Hunsicker, R.P. Bain, and R.D. Rohde The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group N Engl J Med 329 20 1993 1456 1462
2. G.L. Bakris, P. Whelton, M. Weir, A. Mimran, W. Keane, and E. Schiffrin The future of clinical trials in chronic renal disease: outcome of an NIH/FDA/Physician Specialist Conference. Evaluation of Clinical Trial Endpoints in Chronic Renal Disease Study Group J Clin Pharmacol 40 8 2000 815 825
3. S.J. Rosansky, and R.J. Glassock Is a decline in estimated GFR an appropriate surrogate end point for renoprotection drug trials? Kidney Int 85 4 2014 723 727
4. L.A. Stevens, T. Greene, and A.S. Levey Surrogate end points for clinical trials of kidney disease progression Clin J Am Soc Nephrol 1 4 2006 874 884
5. J. Coresh, K. Matsushita, Y. Sang, and et al. GFR decline as an alternative endpoint for kidney failure - meta-analysis of CKD Prognosis Consortium cohorts: a report from an NKF FDA workshop [abstract] J Am Soc Nephrol 24 2013 12A
6. L.A. Inker, H.J. Heerspink, H. Mondal, J. Coresh, T. Greene, and A.S. Levey GFR decline as an endpoint for clinical trials in CKD - a meta-analysis of treatment effects from randomized trials: report of an NKF-FDA workshop [abstract] J Am Soc Nephrol 24 2013 12A
7. L.A. Stevens, J. Coresh, T. Greene, and A.S. Levey Assessing kidney function - measured and estimated glomerular filtration rate N Engl J Med 354 23 2006 2473 2483
8. L.A. Inker, C.H. Schmid, H. Tighiouart, and et al. Estimating glomerular filtration rate from serum creatinine and cystatin C N Engl J Med 367 1 2012 20 29
9. V.R. Dharnidharka, C. Kwon, and G. Stevens Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis Am J Kidney Dis 40 2 2002 221 226
10. G.H. Schardijn, and L.W. Statius van Eps Beta 2-microglobulin: its significance in the evaluation of renal function Kidney Int 32 5 1987 635 641
11. A.O. Grubb Cystatin C - properties and use as diagnostic marker Adv Clin Chem 35 2000 63 99
12. N. Tangri, L.A. Stevens, C.H. Schmid, and et al. Changes in dietary protein intake has no effect on serum cystatin C levels independent of the glomerular filtration rate Kidney Int 79 4 2011 471 477
13. A.C. Baxmann, M.S. Ahmed, N.C. Marques, and et al. Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C Clin J Am Soc Nephrol 3 2 2008 348 354
14. E.L. Knight, J.C. Verhave, D. Spiegelman, and et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement Kidney Int 65 4 2004 1416 1421
15. L.A. Stevens, C.H. Schmid, T. Greene, and et al. Factors other than glomerular filtration rate affect serum cystatin C levels Kidney Int 75 6 2009 652 660
16. B.C. Astor, T. Shafi, R.C. Hoogeveen, and et al. Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population Am J Kidney Dis 59 5 2012 653 662
17. S.P. Juraschek, J. Coresh, L.A. Inker, and et al. Comparison of serum concentrations of beta-trace protein, beta2-microglobulin, cystatin C, and creatinine in the US population Clin J Am Soc Nephrol 8 4 2013 584 592
18. Z. Stanga, S. Nock, P. Medina-Escobar, U.E. Nydegger, M. Risch, and L. Risch Factors other than the glomerular filtration rate that determine the serum beta-2-microglobulin level PLoS One 8 8 2013 e72073
19. N.A. Bhavsar, L.J. Appel, J.W. Kusek, and et al. Comparison of measured GFR, serum creatinine, cystatin C, and beta-trace protein to predict ESRD in African Americans with hypertensive CKD Am J Kidney Dis 58 6 2011 886 893
20. K.S. Spanaus, B. Kollerits, E. Ritz, and et al. Serum creatinine, cystatin C, and beta-trace protein in diagnostic staging and predicting progression of primary nondiabetic chronic kidney disease Clin Chem 56 5 2010 740 749
21. V. Menon, M.G. Shlipak, X. Wang, and et al. Cystatin C as a risk factor for outcomes in chronic kidney disease Ann Intern Med 147 1 2007 19 27
22. C.A. Peralta, R. Katz, M.J. Sarnak, and et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications J Am Soc Nephrol 22 1 2011 147 155
23. C.A. Peralta, M.G. Shlipak, S. Judd, and et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality JAMA 305 15 2011 1545 1552
24. The ARIC Investigators The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives Am J Epidemiol 129 4 1989 687 702
25. 2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol Clin Chem 28 6 1982 1379 1388
26. J. Siedel, E.O. Hagele, J. Ziegenhorn, and A.W. Wahlefeld Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency Clin Chem 29 6 1983 1075 1080
27. C.M. Parrinello, M.E. Grams, D. Couper, and et al. Calibration of analytes over twenty-five years in the Atherosclerosis Risk in Communities Study [abstract] Circulation 129 2014 AP018
28. A.S. Levey, L.A. Stevens, C.H. Schmid, and et al. A new equation to estimate glomerular filtration rate Ann Intern Med 150 9 2009 604 612
29. J.P. Fine, and R.J. Gray A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 94 446 1999 496 509
30. T.C. Turin, J. Coresh, M. Tonelli, and et al. Short-term change in kidney function and risk of end-stage renal disease Nephrol Dial Transplant 27 10 2012 3835 3843
31. J. Coresh, T.C. Turin, K. Matsushita, and et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality JAMA 311 24 2014 2518 2531
32. C.E. Davis The effect of regression to the mean in epidemiologic and clinical studies Am J Epidemiol 104 5 1976 493 498
33. N. Tangri, L.A. Stevens, J. Griffith, and et al. A predictive model for progression of chronic kidney disease to kidney failure JAMA 305 15 2011 1553 1559